At EAU25, Professor Alexander Mottrie presented the latest real-world findings from one of the largest prospective series evaluating the Hugo™ Robotic-Assisted Surgery (RAS) System in urology. This international study, conducted across 21 global sites, included 917 patients who underwent a range of urologic procedures—from radical prostatectomy and nephrectomy to cystectomy and pyeloplasty.
The results confirm that the Hugo™ RAS platform offers a favorable safety and efficacy profile, with a low conversion rate of 0.87%, 2.8% 30-day major complication rate, and a 2.5% readmission rate. Notably, no deaths were reported within 30 days of surgery. Over time, the conversion rate declined as centers gained experience with the system, especially in high-volume sites, showcasing a positive learning curve and adaptability in real-world clinical settings.
These findings reflect a strong endorsement for the safe implementation of Hugo™ RAS into daily urologic practice, opening new opportunities for surgical innovation and improved patient care.
Congratulations to Prof. Mottrie and the many teams worldwide who contributed to this important milestone in robotic urologic surgery.
For more information, you can access the full presentation here: https://lnkd.in/dD3vpykn
